ArticleJournal of affective disorders2025
Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.
Article in Journal of affective disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exclusion of Participants for Substance Use in Clinical Trials.Clinical pharmacology and therapeutics · 2026Article
- Ketamine uropathy: an update on pathophysiology, complications, and treatment options.The Canadian journal of urology · 2026Review
- Substance Use Patterns Across the Sexual Identity Spectrum Among U.S. Individuals.The American journal of psychiatry · 2026Article
- Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights.Journal of psychopharmacology (Oxford, England) · 2026Article
- Associations between substance use treatment and ketamine use: A hypothesis-generating analysis.Addictive behaviors reports · 2026Article
- Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi-modal neuroimaging.Addiction (Abingdon, England) · 2026Article
- Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.Journal of psychoactive drugs · 2026Article
- Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts.Behavioral sciences (Basel, Switzerland) · 2026Article
- Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns.Drug and alcohol dependence reports · 2026Article
- Grayken lessons: a multidisciplinary approach to care for a patient with severe ketamine use disorder.Addiction science & clinical practice · 2026Article
- Trends in nonmedical ketamine use, poisonings, related deaths, pharmaceutical diversions, and law enforcement seizures: results from annual population-based repeated cross-sectional studies.Lancet regional health. Americas · 2025Article
- Non-response to short-term ketamine use for treatment-resistant depression.Pharmacological reports : PR · 2025Observational
- Trends in ketamine use among nightclub attendees in New York City, 2017-2024.The International journal on drug policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundKetamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored.
methodsWe analyzed data from the 2015-2022 National Survey on Drug Use and Health focusing on adults in the US. Trends in past-year ketamine use, overall and by depression status, were estimated separately for 2015-2019 and 2021-2022 due to methodological changes in the survey. We also delineated correlates of ketamine use in each period, focusing on depression, sociodemographic characteristics, and other past-year drug use.
resultsOverall ketamine use prevalence increased from 2015 to 2019 (from 0.11 % to 0.20 %, an 81.8 % increase, p < 0.01) and from 2021 to 2022 (from 0.20 % to 0.28 %, a 40.0 % increase, p < 0.05). From 2015 to 2019, use increased among adults with and without depression (by 139.3 % [p < 0.05] and 66.7 % [p < 0.05], respectively), while from 2021 to 2022, an increase occurred only among those without depression (by 38.9 %, p < 0.05). Multivariable models revealed that depression was associated with increased odds of ketamine use in 2015-2019 (aOR = 1.80, 95 % CI: 1.12-2.89) but not in later years. New sociodemographic correlates emerged in 2021-2022, including adults aged 26-34 and those with a college degree being at higher odds for use. Various drugs (especially ecstasy/MDMA and gamma-hydroxybutyrate) were consistently associated with higher odds of use.
conclusionWe identified differential patterns and correlates of ketamine use over time. Shifts may be related to the evolving ketamine landscape and/or changing survey methodology. Monitoring of use patterns is crucial to inform prevention and harm reduction strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.